1043 related articles for article (PubMed ID: 31733195)
1. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
[TBL] [Abstract][Full Text] [Related]
2. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
5. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
6. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance, polycystic ovary syndrome and metformin.
Pugeat M; Ducluzeau PH
Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostics of polycystic ovary syndrome].
Lazúrová I; Figurová J; Lazúrová Z
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S40-4. PubMed ID: 27124971
[TBL] [Abstract][Full Text] [Related]
10. Endocrine and metabolic characteristics in polycystic ovary syndrome.
Glintborg D
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
[TBL] [Abstract][Full Text] [Related]
11. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).
Siddiqui S; Mateen S; Ahmad R; Moin S
J Assist Reprod Genet; 2022 Nov; 39(11):2439-2473. PubMed ID: 36190593
[TBL] [Abstract][Full Text] [Related]
12. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
13. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
González F
Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
[TBL] [Abstract][Full Text] [Related]
14. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
[TBL] [Abstract][Full Text] [Related]
15. Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Indran IR; Lee BH; Yong EL
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():12-24. PubMed ID: 27118251
[TBL] [Abstract][Full Text] [Related]
16. [Insulin resistance and polycystic ovary syndrome].
Bernard L; Christin-Maître S; Basille C; Chabbert-Buffet N
Gynecol Obstet Fertil; 2003 Feb; 31(2):109-16. PubMed ID: 12718982
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
18. Genetic, hormonal and metabolic aspects of PCOS: an update.
De Leo V; Musacchio MC; Cappelli V; Massaro MG; Morgante G; Petraglia F
Reprod Biol Endocrinol; 2016 Jul; 14(1):38. PubMed ID: 27423183
[TBL] [Abstract][Full Text] [Related]
19. Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.
Singh P; Agress A; Madrigal VK; Magyar C; Ostrzega N; Chazenbalk GD; Dumesic DA
J Clin Endocrinol Metab; 2019 Jul; 104(7):2796-2800. PubMed ID: 30759233
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
